Last Transcript : Transgene

06-29

Analysts' recommendations : Transgene

06-25	Oddo BHF Stays Positive on Transgene
04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
13/10/25	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
19/09/25	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages : Transgene

09-03	Bourse : Snowflake en mode boule de neige, Soitec vise plus haut, Publicis rafle Pepsi
09-03	Une rentrée boursière bien maussade
09-03	Transgene : aucun cas de récidive à trois ans chez les patients traités avec TG4050
09-03	Transgene et NEC annoncent 100 % de survie sans récidive après 3 ans de suivi avec TG4050 et publient les résultats de la Phase 1 dans Nature Communications
07-08	Transgene : Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2026

More news

Managers and Directors : Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	01/06/2023
Lucie Larguier DFI	Director of Finance/CFO	-	27/03/2024
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	02/04/2025

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	27/07/2010
Jean-Luc Bélingard BRD	Director/Board Member	76	19/06/2013
Alain Mérieux BRD	Director/Board Member	88	01/01/2007

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

09-24 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	€0.8620	-2.60%	264,939
03/09/26	€0.8850	+12.45%	1,110,882
02/09/26	€0.7870	-0.38%	39,654
01/09/26	€0.7900	-1.13%	43,706
31/08/26	€0.7990	-0.37%	45,873

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8620EUR

Average target price

1.100EUR

Spread / Average Target

+27.61%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Euronext Paris 23:55:00 04/09/2026 HKT			5-day change	1st Jan Change
0.8620 ^EUR	-2.60%		+7.48%	-10.21%

09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-03	Transgene: no cases of recurrence at three years among patients treated with TG4050

Market Cap	236M 274M 222M 203M 380M 25.9B 381M 2.62B 1.02B 13.29B 1.03B 1.01B 42.82B	P/E 2026 *	-6.16x	P/E 2027 *	-3.92x
Enterprise Value	167M 194M 157M 143M 268M 18.31B 269M 1.86B 720M 9.39B 728M 712M 30.27B	EV / Sales 2026 *	23.2x	EV / Sales 2027 *	31.7x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
CBOE	TNGp	Real-time
OTC Markets	TRGNF	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Börse Stuttgart	TGNA	Delayed
Boerse Muenchen	TGNA	Real-time

09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-03	Transgene: no cases of recurrence at three years among patients treated with TG4050
09-03	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation : Transgene

Chart: Transgene

Latest news : Transgene

Last Transcript : Transgene

Analysts' recommendations : Transgene

Press Releases : Transgene

News in other languages : Transgene

Quotes and Performance

Price Extremes

Managers and Directors : Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

09-03	Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications	GL
07-08	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026	GL
06-25	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026	GL
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	GL
05-26	Transgene : Investor presentation (20260526 Transgene Investor Presentation)	PU

1 day	-2.60%
1 week	+7.48%
Current month	+7.88%
1 month	+21.75%
3 months	+9.11%
6 months	+1.17%
Current year	-10.21%

1 week	0.78	0.97
1 month	0.71	0.97
Current year	0.7	1.03
1 year	0.7	1.5
3 years	0.53	1.86
5 years	0.53	2.99
10 years	0.53	3.79

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/12/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
2/12/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
2/8/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-2.60%	+7.48%	-21.64%	-50.74%	274M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+86.44%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+378.92%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-14.95%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+12.54%	25.74B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-18.61%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+368.10%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+531.89%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+164.98%	14.62B
Average	-1.50%	+0.98%	+36.27%	+154.75%	27.94B
Weighted average by Cap.	-1.52%	+0.18%	+38.32%	+137.16%

	2026 *	2027 *
Net sales	7.2M 8.37M 6.77M 6.19M 11.58M 790M 11.61M 80.05M 31.06M 405M 31.42M 30.73M 1.31B	7.2M 8.37M 6.77M 6.19M 11.58M 790M 11.61M 80.05M 31.06M 405M 31.42M 30.73M 1.31B
Net income	-38.2M -44.39M -35.94M -32.83M -61.42M -4.19B -61.59M -425M -165M -2.15B -167M -163M -6.93B	-61.6M -71.59M -57.96M -52.94M -99.04M -6.76B -99.31M -685M -266M -3.47B -269M -263M -11.17B
Net Debt	-69.2M -80.42M -65.11M -59.48M -111M -7.59B -112M -769M -299M -3.9B -302M -295M -12.55B	-7.7M -8.95M -7.24M -6.62M -12.38M -845M -12.41M -85.61M -33.22M -433M -33.6M -32.87M -1.4B